FOXO6 and hepatocellular carcinoma: After the PI3K/AKT signaling pathway is activated by 740Y-P (a PI3K activator) or inhibited by LY294002 (a PI3K inhibitor), FOXO6 knockdown affects resistance to paclitaxel chemotherapy, cytotoxicity, and glycolysis in HCC cells.